Hussman Strategic Advisors Inc. Has $3.04 Million Stock Position in Amgen Inc. $AMGN

Hussman Strategic Advisors Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 60.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,400 shares of the medical research company’s stock after purchasing an additional 3,150 shares during the period. Hussman Strategic Advisors Inc.’s holdings in Amgen were worth $3,042,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Croban grew its stake in Amgen by 2.4% during the second quarter. Croban now owns 4,078 shares of the medical research company’s stock worth $1,477,000 after buying an additional 94 shares in the last quarter. ProVise Management Group LLC raised its position in shares of Amgen by 1.3% in the 2nd quarter. ProVise Management Group LLC now owns 16,496 shares of the medical research company’s stock valued at $5,974,000 after buying an additional 213 shares in the last quarter. Bryn Mawr Trust Advisors LLC raised its position in shares of Amgen by 7.6% in the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 9,560 shares of the medical research company’s stock valued at $3,462,000 after buying an additional 678 shares in the last quarter. Hardy Reed LLC lifted its holdings in shares of Amgen by 65.8% during the 2nd quarter. Hardy Reed LLC now owns 1,129 shares of the medical research company’s stock worth $409,000 after acquiring an additional 448 shares during the period. Finally, Massachusetts Wealth Management lifted its holdings in shares of Amgen by 0.8% during the 2nd quarter. Massachusetts Wealth Management now owns 6,347 shares of the medical research company’s stock worth $2,299,000 after acquiring an additional 50 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AMGN. Robert W. Baird lifted their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Sanford C. Bernstein upped their target price on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Guggenheim raised their target price on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a report on Monday. BMO Capital Markets lifted their price target on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Mizuho boosted their price target on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $372.39.

Amgen Price Performance

AMGN stock opened at $415.21 on Friday. The company has a 50 day simple moving average of $370.57 and a 200 day simple moving average of $358.93. The stock has a market cap of $224.47 billion, a price-to-earnings ratio of 25.81, a P/E/G ratio of 3.88 and a beta of 0.41. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $421.79. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the prior year, the firm earned $6.02 EPS. The firm’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts anticipate that Amgen Inc. will post 22.78 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. This represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last quarter. 0.85% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.